Track topics on Twitter Track topics that are important to you
Adults with type 2 diabetes assigned the once-weekly GLP-1 receptor agonist semaglutide in addition to metformin therapy experienced a greater reduction in HbA1c and body weight after 40 weeks compared with those assigned once-weekly dulaglutide and metformin, Novo Nordisk announced in a press release.Results from the SUSTAIN 7 trial demonstrated that patients assigned 0.5 mg weekly semaglutide (Novo Nordisk) saw an HbA1c reduction of 1.5% over 40 weeks vs. a 1.1% reduction for those assigned 0.75 mg weekly dulaglutide (Trulicity, Eli Lilly), from a mean baseline HbA1c of 8.2%. Patients assigned 1 mg semaglutide saw a 1.8% HbA1c reduction vs. a 1.4% reduction for those assigned 1.5 mg dulaglutide. Additionally, more patients achieved at least 5% body-weight loss at 40 weeks when assigned 0.5 mg semaglutide vs. 0.75 dulaglutide (44% vs. 23%), with a greater difference for those assigned 1 mg semaglutide vs. 1.5 mg dulaglutide (63% vs. 30%).NEXT ARTICLE
The Top 100 Pharmaceutical Companies
Top 10 biotech and pharmaceutical companies worldwide based on market value in 2015 2015 ranking of the global top 10 biotech and pharmaceutical companies based on revenue (in billion U.S. dollars) Johnson & Johnson, U.S. 74...